New combo therapy fights back against stubborn blood cancers
NCT ID NCT05583149
Summary
This study is testing if adding the drug acalabrutinib to a personalized cell therapy (liso-cel) is safe and effective for adults with aggressive B-cell lymphomas that have come back or not responded to at least two prior treatments. Participants receive a one-time infusion of the cell therapy and take the drug orally for up to a year, with long-term follow-up. The goal is to see if this combination can better control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.